Last reviewed 2026-04-23 · How we verify

Pure chemotherapy（Xelox）

Xelox is a chemotherapy regimen combining capecitabine and oxaliplatin that inhibits DNA synthesis and causes DNA cross-linking to kill rapidly dividing cancer cells.

Xelox is a chemotherapy regimen combining capecitabine and oxaliplatin that inhibits DNA synthesis and causes DNA cross-linking to kill rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Gastric cancer, Breast cancer (adjuvant and metastatic settings).

At a glance

Mechanism of action

Capecitabine is a fluoropyrimidine carbamate that is converted to 5-fluorouracil (5-FU), which inhibits thymidylate synthase and disrupts nucleotide synthesis. Oxaliplatin is a platinum-based agent that forms DNA adducts and cross-links, preventing DNA replication and transcription. Together, these agents provide synergistic cytotoxic effects against cancer cells.

Approved indications

• Metastatic colorectal cancer
• Gastric cancer
• Breast cancer (adjuvant and metastatic settings)

Common side effects

• Neutropenia
• Diarrhea
• Nausea/vomiting
• Hand-foot syndrome
• Peripheral neuropathy
• Anemia
• Thrombocytopenia

Key clinical trials

• Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Pure chemotherapy（Xelox） CI brief — competitive landscape report
• Pure chemotherapy（Xelox） updates RSS · CI watch RSS
• The First People's Hospital of Hefei portfolio CI